Belgium· BE-AMP-SAM117451-00
Holoxan 1 g
A ifosfamide product containing ifosfamide, registered in Belgium by Baxter. The same ATC class is registered in 15 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Ifosfamide is registered in 15 of 19 countries.
Countries holding a registration under ATC L01AA06 (ifosfamide), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 9 of them publish a price we can compare per daily dose
Ifosfamide · ATC L01AA06
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of ifosfamide costs, country by country.
Normalised to the WHO defined daily dose (0.7 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Ifosfamide · price per daily dose (0.7 g)
USD · FX 28 Sept 2026
- CH Switzerland$52.67
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Ifosfamide
- Manufacturer
- Baxter
- Country
- Belgium (BE)
- ATC code
- L01AA06
- ATC class
- Ifosfamide
- Defined daily dose
- 0.7 g, P
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 2
- be_apb0098202
- be_apb0729533
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
514 interactions on record for ifosfamide.
Graded by severity as the source publishes them — 41 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Ifosfamide · interactions on record
514 records
- 41 severe
- 385 moderate
- 16 minor
- 72 info
Most severe, free to view
- Nalidixic acidJ01MB02severe
- CidofovirJ05AB12severe
- ThiotepaL01AC01severe
- CladribineL01BB04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Ifosfamide in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- PolandHoloxanBaxter Polska Sp. z o.o.
- CzechiaHOLOXANBaxter Oncology GmbH, Halle
- United StatesIFEXBaxter Healthcare Corporation
- United KingdomIfosfamide 1g powder for concentrate for solution for injection vialsAlliance Healthcare (Distribution) Ltd
- FinlandHoloxanOrifarm Oy
- NorwayHoloxanBaxter
- GermanyHoloxanBaxter Deutschland Gmbh
- SwedenHoloxan 1000 mg Pulver till injektions-/infusionsvätska, lösningBaxter Medical AB
Authorised across Europe · EMA
The same active substance is authorised in 28 EEA countries. Names it is sold under:
- Austria · Holoxan
- Bulgaria · Холоксан
- Czechia · Holoxan
- Germany · Holoxan, Ifo-Cell
- Denmark · Holoxan
- Estonia · Holoxan
- Spain · Tronoxal
- Finland · Holoxan
- France · Holoxan, Ifosfamide Eg
- United Kingdom (Northern Ireland) · Ifosfamide Baxter Healthcare
- Greece · Holoxan
- Croatia · Holoxan
- Hungary · Holoxan
- Ireland · Mitoxana
- Iceland · Holoxan
- Italy · Holoxan
- Lithuania · Holoxan
- Luxembourg · Holoxan
- Latvia · Holoxan
- Malta · Mitoxana
- Netherlands · Holoxan
- Norway · Holoxan
- Poland · Holoxan
- Portugal · Holoxan
- Romania · Holoxan
- Sweden · Holoxan
- Slovenia · Holoxan
- Slovakia · Holoxan
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f7d0c082-b582-4449-b458-e6205d2078d4 GET /v1/drugs/f7d0c082-b582-4449-b458-e6205d2078d4?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Powder for solution for injection",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Holoxan 1 g",
"name_fr": "Holoxan 1 g",
"name_nl": "Holoxan 1 g",
"amp_code": "SAM117451-00",
"strengths": [
"1000.0000"
],
"pack_count": 2,
"substances": [
"Ifosfamide"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Ifosfamide",
"authorisation_numbers": [
"BE117451"
]
}See everything about ifosfamide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.